25 completed. 25 Phase 2, 8 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 25 |
| Phase 1 | 8 | Completed 8 |
| Phase 3 | 3 | Completed 3 |
Follow Rickets: new trials by email Literature Review of Rickets trials Research Report on Rickets
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia Burosumab - Fibrous Dysplasia Of Bone | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 12 | 2022-12-07 | 2026-02-02 |
| Effectiveness of Vitamin C Supplementation in Treatment of Rickets Vit C - Nutritional Rickets, Bone Turnover Rate Disorder | Phase 2 / Phase 3 | Completed | Cairo University | 88 | 2022-03-01 | 2023-03-08 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Burosumab - X-linked Hypophosphatemia (XLH) | Phase 1 / Phase 2 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 16 | 2020-02-26 | 2024-11-07 |
| Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia 68Ga-DOTATATE PET/CT - Osteomalacia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 18 | 2019-01-31 | 2025-04-30 |
| The Effect of Etelcalcetide on CKD-MBD Etelcalcetide - Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy | Phase 2 | Completed | Thomas Nickolas, MD MS | 22 | 2018-09-06 | 2023-09-21 |
| The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis Dialysate magnesium (1.0 mmol/L), Dialysate magnesium (0.5 mmol/L) - Endstage Renal Disease | Phase 2 | Completed | Iain Bressendorff | 59 | 2016-12-01 | 2018-06-06 |
| Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Burosumab - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 13 | 2016-05-05 | 2024-05-06 |
| Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) KRN23 - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 20 | 2015-01-30 | 2024-05-06 |
| Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) burosumab - X-linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 52 | 2014-07-02 | 2024-05-06 |
| An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 23 | 2012-02-01 | 2024-06-18 |
| Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder Etelcalcetide - Secondary Hyperparathyroidism | Phase 2 | Completed | KAI Pharmaceuticals | 37 | 2011-12-05 | 2017-04-11 |
| A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia KRN23 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 29 | 2011-04-01 | 2024-06-18 |
| Vitamin D Supplementation in Breastfeeding Women Vitamin D3 - Vitamin D Deficiency, Rickets | Phase 2 / Phase 3 | Completed | Mayo Clinic | 80 | 2010-12-01 | 2013-04-30 |
| Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia | Phase 2 / Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 69 | 2010-07-01 | 2019-03-13 |
| Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 19 | 2010-06-01 | 2019-03-13 |
| Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP) Asfotase Alfa - Hypophosphatasia (HPP) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 12 | 2010-04-01 | 2019-03-13 |
| Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia (HPP) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2009-09-01 | 2019-04-01 |
| Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 10 | 2009-04-01 | 2019-03-13 |
| Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia (HPP) | Phase 1 / Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 11 | 2008-09-01 | 2019-04-01 |
| The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients Niacinamide, Placebo - Hyperphosphatemia | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 17 | 2006-10-01 | 2007-07-30 |
Showing 20 of 25. Sign in to see all of them.
Osteomalacia (9) · Bone Diseases (7) · Chronic Kidney Disease-Mineral and Bone Disorder (7) · Familial Hypophosphatemic Rickets (7) · Hypophosphatasia (6) · Vitamin D Deficiency (3) · Bone Diseases, Metabolic (2) · Hyperparathyroidism, Secondary (2) · Kidney Failure, Chronic (2) · Fibrous Dysplasia of Bone (1) · Fibrous Dysplasia, Polyostotic (1) · Hyperparathyroidism (1) · Hyperphosphatemia (1) · Infant Nutrition Disorders (1)
Avitaminosis (25) · Calcium Metabolism Disorders (25) · Deficiency Diseases (25) · Malnutrition (25) · Metabolic Diseases (25) · Musculoskeletal Diseases (25) · Nutrition Disorders (25) · Nutritional and Metabolic Diseases (25) · Bone Diseases, Metabolic (23) · Vitamin D Deficiency (22) · Bone Diseases (18) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Male Urogenital Diseases (14)
burosumab (7) · asfotase alfa (6) · Calcitriol (2) · Cholecalciferol (2) · Growth Hormone (2) · etelcalcetide hydrochloride (2) · 1 alpha-hydroxyergocalciferol (1) · Calcium (1) · Calcium Carbonate (1) · Cinacalcet (1) · Niacinamide (1) · Sevelamer (1)
Alexion Pharmaceuticals, Inc. (6) · Kyowa Kirin, Inc. (3) · Kyowa Kirin Co., Ltd. (2) · Mayo Clinic (2) · Amgen (1) · Bicetre Hospital (1) · Cairo University (1) · Iain Bressendorff (1) · KAI Pharmaceuticals (1) · Kyowa Kirin Pharmaceutical Development Ltd (1) · National Center for Research Resources (NCRR) (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Thomas Nickolas, MD MS (1) · University of Toronto (1)
United States (17) · Canada (7) · United Kingdom (5) · France (3) · Italy (2) · Spain (2) · United Arab Emirates (2) · Australia (1) · Austria (1) · Denmark (1) · Egypt (1) · Germany (1) · Japan (1) · Netherlands (1) · Russia (1)
Amy Zhang, PhD (2) · Alison M Boyce, M.D. (1) · Daniel O Young, MD (1) · Fatina Fadel, Prof (1) · Gregory Bell, MD (1) · Isidro B Salusky, MD (1) · Isidro B. Salusky (1) · Matthew Drake, MD (1) · Stephen M Broski, MD (1) · Thomas Nickolas, MD, MS (1) · Thomas Thacher, MD (1)
PMID 26529632, PMID 32417537, PMID 32762706, PMID 25919461, PMID 27699270, PMID 32721016, PMID 39151033, PMID 40576086, PMID 18397701, PMID 19244376, PMID 19776051, PMID 22397652, PMID 24120120, PMID 24290111, PMID 26073451, PMID 28822957, PMID 29486367, PMID 29791829, PMID 30558909, PMID 30638856, PMID 30811537, PMID 30969260, PMID 34636899, PMID 36072994, PMID 37574661, PMID 42044650